Login to Your Account



Kymab Ramps Up Efforts for Antibody Partnerships, R&D

By Nuala Moran
Staff Writer

Wednesday, October 31, 2012
LONDON – Kymab Ltd. called up two industry veterans to help with the commercialization of its new platform technology for generating monoclonal antibodies in transgenic mice, as it prepares both to out-license access to the technology and use it to start an internal drug discovery effort.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription